Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

被引：0
|
作者：
Yang, J. [1 ]
Cheng, Y. [2 ]
Murakami, H. [3 ]
Yang, P-C. [1 ]
He, J. [4 ]
Nakagawa, K. [5 ]
Kang, J. H. [6 ]
Kim, J-H. [7 ]
Hozak, R. [8 ]
Nguyen, T. [9 ]
Wang, X. [10 ]
Enatsu, S. [11 ]
Puri, T. [12 ]
Orlando, M. [13 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[2] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Peoples R China
[3] Shizuoka Canc Ctr, Dept Oncol, Shizuoka, Japan
[4] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Oncol, Guangzhou, Guangdong, Peoples R China
[5] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[6] Catholic Univ Korea, Dept Med Oncol, Seoel, South Korea
[7] CHA Univ, CHA Bundang Med Ctr, Dept Oncol, Gyeonggi Do, South Korea
[8] Eli Lilly & Co, Oncol Business Unit, Indianapolis, IN 46285 USA
[9] Eli Lilly & Co, Oncol Tailoring Biomarker Stat, Indianapolis, IN 46285 USA
[10] Eli Lilly & Co, Med Dev Unit, Shanghai, Peoples R China
[11] Eli Lilly Japan KK, Med Dev Unit, Kobe, Hyogo, Japan
[12] Eli Lilly & Co, Med Affairs, Gurgaon, India
[13] Eli Lilly & Co, Emerging Markets Med Affairs, Buenos Aires, Argentina
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw383.40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1240P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schaer, S.
    Schmid, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L. A.
    Von Briel, T.
    Waibel, C.
    De Nicola, L. Wannesson
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W-D.
    Siano, M.
    Britschgi, C.
    Frueh, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1585
  • [32] Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Liang, Jun
    Kang, Jin-Hyoung
    Xiu, Qingyu
    Chen, Yuh-Min
    Blair, Julie Michelle
    Peng, Guangbin
    Linn, Carlos
    Orlando, Mauro
    LUNG CANCER, 2012, 77 (02) : 346 - 352
  • [33] Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
    Zhou, Caicun
    Wu, Yi Long
    Liu, Xiaoqing
    Wang, Changli
    Chen, Gongyan
    Feng, Ji Feng
    Zhang, Shucai
    Wang, Jie
    Zhou, Songwen
    Ren, Shengxiang
    Lu, Shun
    Zhang, Li
    Hu, Cheng-ping
    Luo, Yi
    Chen, Lei
    Ye, Ming
    Huang, Jianan
    Zhi, Xiuyi
    Zhang, Yiping
    Xiu, Qingyu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Epidermal Growth Factor Receptor (EGFR) Expression as a Predictive Biomarker of Survival in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Therapy With Cetuximab Combined With Chemotherapy in the FLEX Trial
    O'Byrne, K.
    Paz-Ares, L.
    Pereira, J. R.
    von Pawel, J.
    Ramlau, R.
    Stoerkel, S.
    Schumacher, K. M.
    von Heydebreck, A.
    Celik, I.
    Pirker, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S591 - S591
  • [35] Phase II study of bevacizumab, cisplatin, and pemetrexed as first-line chemotherapy for advanced nonsquamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type.
    Murakami, Shuji
    Saito, Haruhiro
    Karino, Fumi
    Kondo, Tetsuro
    Oshita, Fumihiro
    Yamada, Kouzo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] A review of prognostic factors for patients with epidermal growth factor receptor mutation positive advanced non small cell lung cancer (EGFR plus NSCLC)
    Itotani, R.
    Marumo, S.
    Fukui, M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S129 - S129
  • [37] Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M plus ) non-small cell lung cancer (NSCLC): Comparative analysis of Asian and non-Asian patients from two randomized trials
    Schuler, M.
    Sequist, L. V.
    Yang, J. C.
    Yamamoto, N.
    O'Byrne, K. J.
    Mok, T.
    Geater, S. L.
    Massey, D.
    Wind, S.
    O'Brien, D.
    Lorence, R.
    Wu, Y. -L.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 90 - 90
  • [38] Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
    Uchibori, Ken
    Satouchi, Miyako
    Sueoka-Aragane, Naoko
    Urata, Yoshiko
    Sato, Akemi
    Imamura, Fumio
    Inoue, Takako
    Tachihara, Motoko
    Kobayashi, Kazuyuki
    Katakami, Nobuyuki
    Kokan, Chiyuki
    Hirashima, Tomonori
    Iwanaga, Kentaro
    Mori, Masahide
    Aoe, Keisuke
    Morita, Satoshi
    Negoro, Shunichi
    LUNG CANCER, 2018, 124 : 65 - 70
  • [39] The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC)
    Neal, J. W.
    Pennell, N. A.
    Govindan, R.
    Heist, R. S.
    Shaw, A. T.
    Muzikansky, A.
    Janne, P. A.
    Lynch, T. J.
    Azzoli, C. G.
    Sequist, L. V.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S209 - S209
  • [40] The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Neal, Joel W.
    Pennell, Nathan A.
    Govindan, Ramaswamy
    Lanuti, Michael
    Rosovsky, Rachel Pam Greenerger
    Heist, Rebecca Suk
    Shaw, Alice Tsang
    Temel, Jennifer S.
    Muzikansky, Alona
    Janne, Pasi A.
    Lynch, Thomas James
    Azzoli, Christopher G.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345